PT  - JOURNAL ARTICLE
AU  - Inchauste, Lucia
AU  - Nurtop, Elif
AU  - Machicado, Lissete Bautista
AU  - Roth, Yanine Leigue
AU  - Gonzales, Shirley Lenz
AU  - Herrera, Maria Luisa
AU  - Villafan, Katty Mina
AU  - Mamani, Pedro Mamani
AU  - Espinoza, Marcelo Ramos
AU  - Pavel Suarez, Juan Carlos
AU  - Garcia Copa, Juan Cansio
AU  - Zabala, Yitzhak Leigue
AU  - Cardozo, Etzel Arancibia
AU  - Gallian, Pierre
AU  - de Lamballerie, Xavier
AU  - Priet, Stéphane
TI  - Improving SARS-CoV-2 variants monitoring in the absence of genomic surveillance capabilities: a serological study in Bolivian blood donors in October 2021 and June 2022
AID  - 10.1101/2023.11.23.23298957
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.11.23.23298957
4099  - http://medrxiv.org/content/early/2023/11/23/2023.11.23.23298957.short
4100  - http://medrxiv.org/content/early/2023/11/23/2023.11.23.23298957.full
AB  - Unlike genomic data, serological data have not been previously leveraged to evaluate the SARS-CoV-2 variants circulation. In Bolivia, sustained genomic surveillance capacities were lacking especially at the beginning of the pandemic. In 2021 and 2022 we estimated the prevalence of anti-SARS-CoV-2 antibodies in Bolivian blood donors and explored the feasibility of using virus serum neutralization data for variants thought to have circulated to map their circulation across all departments over a year-long follow-up period. Anti-S1 and anti-NCP SARS-CoV-2 IgGs were studied, along with virus neutralization tests for ancestral-D614G, Gamma, Delta, and Omicron BA.1 lineages of SARS-CoV-2. Between 2021 and 2022, the overall prevalence of anti-S1 and anti-NCP antibodies increased reaching values over 90%, demonstrating that a large proportion of the Bolivian population was no longer naïve to the virus. Viral neutralization data, analyzed through multiple approaches, revealed the spread of the Gamma variant up to 2021, particularly impacting northern departments. In 2022, Gamma continued to circulate in southernmost departments of the country and the emergence of Omicron BA.1 was detected. These trends align with publicly available genomic data from neighboring countries. Our serological analyses successfully identified both new antigenic groups, such as Omicron BA.1, and individual variants related to previously circulating groups, such as Delta. The study contributes insights into overall population immunity to SARS-CoV-2 and variant-specific immunity levels across different regions of Bolivia. It also emphasizes the potency of seroprevalence studies in informing public health decisions and underscore their value in capturing the initial phases of emerging epidemics when variant diversity is limited, facilitating timely genomic surveillance setup.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the French National Research Institute for Sustainable Development (IRD), the project EMERGEN-PRI #22275 of the ANRS I MIE (INSERM), and the European Union's Horizon 2020 research and innovation program (European Virus Archive Global, grant agreement No. 871029).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the Dr. Mario Ortiz Suarez hospital, Santa Cruz de la Sierra, Bolivia (Number FWA0002686) and the National Blood Program from the Ministry of Health and Sports of Bolivia gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors and after acceptance by the ethics committee and the National Blood Program from the Ministry of Health and Sports of Bolivia